Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-DADA: Daratumumab in Transplant-ineligible Myeloma Patients
NCT04656951Phase 2Active, not recruiting
- Sponsor
- University of Cologne
- Start
- Jun 2021
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by University of Cologne. Started Jun 2021; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04656951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656951.